%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-03-28T09:30:55-05:00
2017-03-28T09:30:55-05:00
2017-03-28T09:30:55-05:00
Adobe InDesign CC 2017 (Windows)
uuid:1648ac04-7188-482c-a97f-ce746686f082
xmp.did:5e04fea8-b29b-c643-9d13-a71790cd99a6
xmp.id:7c6cd516-8ed3-104e-a213-a14532befb9c
proof:pdf
xmp.iid:c57d9dfa-36c2-814f-bd0a-8682cc15b941
xmp.did:4d592983-c0e2-bc4d-a0bc-3a65454a3fae
xmp.did:5e04fea8-b29b-c643-9d13-a71790cd99a6
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-03-28T09:30:55-05:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
8 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
10 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
11 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/TrimBox[0.0 0.0 581.102 765.354]/Type/Page>>
endobj
30 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0.04 Tc -0.04 Tw 9 0 0 9 48.189 32.9076 Tm
(80)Tj
-0.01 Tc 0.063 Tw 0 71.984 TD
[(La bibliograf\355a recomienda como aproximaci\363n diagn\363stica)-10.4 ( )]TJ
-0.095 Tw 0 -1.111 TD
[(basarse en manifestaciones cl\355nicas dependientes del \363rgano)-9.6 ( )]TJ
0.255 Tw T*
[(afectado y complementarse con ex\341menes auxiliares de)-10.4 ( )]TJ
0.085 Tw T*
[(laboratorio )-0.7 (e )-0.6 ( )-0.7 (im\341genes. )-0.6 (El )-0.6 (diagn\363stico )-0.7 (diferencial )-0.7 (incluye)-10.5 ( )]TJ
0 Tw T*
(enfermedades end\351micas seg\372n la procedencia)Tj
0.03 Tc 5 0 0 5 234.6109 644.7658 Tm
( \(12\))Tj
0 Tc 9 0 0 9 245.7833 640.7658 Tm
(.)Tj
-0.01 Tc 0.212 Tw -21.955 -2.222 Td
[(El cultivo de micobacterias es la prueba dorada para el)-9.9 ( )]TJ
0.045 Tw T*
[(diagn\363stico. En )17.8 (TBOA)55.3 ( tiene baja tasa de aislamiento por lo)-9.6 ( )]TJ
-0.028 Tw T*
[(que su uso diagn\363stico es limitado. Se debe tener en cuenta)-10.4 ( )]TJ
0.165 Tw 0 -1.111 TD
[(que el cultivo de l\355quido sinovial no es definitivo, puede)-10.4 ( )]TJ
0.185 Tw 0 -1.111 TD
(dar resultados positivos hasta en 79% de los casos)Tj
0.03 Tc 5 0 0 5 256.9943 584.7658 Tm
( \(8\))Tj
-0.01 Tc -0.291 Tw 9 0 0 9 266.318 580.7658 Tm
[(. )-475.9 (En)-10.4 ( )]TJ
0.044 Tw -24.237 -1.111 Td
[(casos de dif\355cil aislamiento, se puede llegar a requerir una)-10.3 ( )]TJ
-0.007 Tw T*
[(biopsia de tejido a partir de la cual cultivar el bacilo, como)-9.6 ( )]TJ
0 Tw T*
(es nuestro caso.)Tj
-0.07 Tw T*
[(El estudio histopatol\363gico puede ser problem\341tico ya que los)-9.8 ( )]TJ
0.039 Tw 0 -1.111 TD
[(sitios de infecci\363n son poco accesibles y hay resistencia de)-10.4 ( )]TJ
-0.046 Tw 0 -1.111 TD
(los pacientes a estudios invasivos)Tj
0.03 Tc 5 0 0 5 177.6887 524.7658 Tm
( \(6\))Tj
-0.01 Tc 9 0 0 9 185.8593 520.7658 Tm
[(. Este caso es peculiar ya)-10.4 ( )]TJ
0.078 Tw -15.297 -1.111 Td
[(que )-0.7 (los )-0.7 (granulomas )-0.7 (caseificantes )-0.6 (respaldan )-0.7 (el )-0.7 (diagn\363stico;)-10.2 ( )]TJ
0.024 Tw T*
[(as\355, )-0.7 (es )-0.7 (recomendable )-0.7 (realizar )-0.7 (estudios )-0.7 (histol\363gicos, )-0.7 (a\372n )-0.7 (los)-9.8 ( )]TJ
0 Tw T*
(estudios microbiol\363gicos sean negativos)Tj
0.03 Tc 5 0 0 5 204.9167 494.7658 Tm
( \(7\))Tj
0 Tc 9 0 0 9 213.317 490.7658 Tm
(.)Tj
-0.01 Tc -0.052 Tw -18.348 -2.222 Td
[(Muchos casos en P)47.3 (er\372 inician tratamiento emp\355rico sin llegar)-9.6 ( )]TJ
0.167 Tw T*
[(a confirmaci\363n histol\363gica o microbiol\363gica. Concretar el)-9.9 ( )]TJ
0.14 Tw T*
[(diagn\363stico de )18 (T)0.5 (BOA)55.4 ( es un reto que puede tardar incluso)-9.6 ( )]TJ
0.01 Tw 0 -1.111 TD
(a\361os)Tj
0.03 Tc 0 Tw 5 0 0 5 65.9476 444.7658 Tm
( \(13\))Tj
0 Tc 9 0 0 9 77.12 440.7658 Tm
(.)Tj
-0.01 Tc 0.22 Tw -3.215 -1.111 Td
[(El tratamiento de )18.3 (TBOA)55.3 ( requiere de 12 meses. Mientras)-9.7 ( )]TJ
0.141 Tw 0 -1.111 TD
[(que el manejo quir\372rgico se orienta a mejorar la calidad)-10.1 ( )]TJ
0.238 Tw T*
(de vida del paciente debido a lesiones secuelares)Tj
0.03 Tc 5 0 0 5 258.4283 414.7658 Tm
( \(9\))Tj
-0.01 Tc 9 0 0 9 268.0168 410.7658 Tm
[(; el)-9.9 ( )]TJ
0.024 Tw -24.425 -1.111 Td
[(tratamiento m\351dico de acuerdo a la norma t\351cnica vigente)-10.4 ( )]TJ
-0.033 Tw T*
[(en nuestro pa\355s consiste de una primera fase con isoniacida,)-10.1 ( )]TJ
0.115 Tw T*
[(Rifampicina, Etambutol y P)47.3 (irazinamida por 2 meses y una)-10.4 ( )]TJ
0.274 Tw T*
[(segunda )-0.7 (fase )-0.7 (de )-0.7 (Isoniacida )-0.7 (y )-0.7 (Rifampicina )-0.7 (por )-0.7 (10 )-0.7 (meses)-9.8 ( )]TJ
0.03 Tc -0.03 Tw 5 0 0 5 48.189 364.7658 Tm
(\(12\))Tj
-0.01 Tc 0.102 Tw 9 0 0 9 57.705 360.7658 Tm
[(. El desbridamiento y la artrodesis son considerados los)-9.8 ( )]TJ
0.174 Tw -1.057 -1.111 Td
[(tratamientos )-0.7 (quir\372rgicos )-0.7 (principales )-0.7 (en )-0.7 (fases )-0.7 (finales, )-0.7 (con)-10.4 ( )]TJ
0.105 Tw T*
[(buena evoluci\363n a una articulaci\363n estable y no dolorosa;)-10.1 ( )]TJ
0.394 Tw T*
[(el )-0.7 (desbridamiento )-0.7 (completo )-0.8 (es )-0.8 (crucial )-0.7 (y )-0.8 (disminuye )-0.7 (la)-10.4 ( )]TJ
0.01 Tw T*
(recurrencia)Tj
0.03 Tc 0 Tw 5 0 0 5 93.5525 324.7658 Tm
( \(14\))Tj
0 Tc 9 0 0 9 104.7248 320.7658 Tm
(. )Tj
-0.01 Tc -0.054 Tw -6.282 -2.222 Td
[(Finalmente, como se refleja en nuestro caso, la )17.9 (TBOA)55.3 ( puede)-10.4 ( )]TJ
0.335 Tw T*
[(ser )-0.7 (err\363neamente )-0.7 (diagnosticada )-0.7 (por )-0.7 (m\372ltiples )-0.7 (factores.)-10.2 ( )]TJ
0.275 Tw T*
[(Se )-0.7 (resalta )-0.7 (la )-0.6 (importancia )-0.7 (de )-0.6 (no )-0.7 (descartar )-0.6 (este )-0.6 (tipo )-0.7 (de)-10.4 ( )]TJ
0.107 Tw 0 -1.111 TD
[(manifestaci\363n de tuberculosis, especialmente en casos de)-10.4 ( )]TJ
0.095 Tw 0 -1.111 TD
[(artritis cr\363nica con estudios comunes negativos, y a pesar)-9.7 ( )]TJ
0 Tw T*
(de la ausencia de signos de foco primario.)Tj
0.062 Tw 0 -2.222 TD
[(Desafortunadamente las personas de bajos recursos siguen)-10.3 ( )]TJ
-0.078 Tw 0 -1.111 TD
[(siendo los sujetos m\341s vulnerables a la infecci\363n y con mayor)-9.6 ( )]TJ
0 Tw T*
(riesgo de complicaciones debido a su tard\355a atenci\363n.)Tj
/CS0 cs 1 scn
/GS1 gs
/TT1 1 Tf
0 Tc 0 -2.311 TD
(REFERENCIAS BIBLIOGR\301FICAS)Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.01 Tc 0.718 Tw 8 0 0 8 48.189 169.9658 Tm
(1.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Espinosa-Gimeno )55.4 (A, Mart\355nez-Sanz J, )55.5 (Asong-Engonga L,)-10.2 ( )]TJ
0.551 Tw 0 -1.25 TD
[(R)40.5 (odr\355guez-Zapata M. P)47.3 (rotocolo diagn\363stico y terap\351utico)-9.6 ( )]TJ
0.368 Tw T*
[(de las tuberculosis extrapulmonares. Medicine - P)47.2 (rograma)-10.4 ( )]TJ
0.626 Tw T*
[(de )-0.7 (Formaci\363n )-0.6 (M\351dica )-0.6 (Continuada )54.5 (Acreditado )-0.6 ([Internet].)-10.2 ( )]TJ
0.467 Tw T*
[(2014 )-0.6 ([cited )-0.6 (10 )-0.6 (October )-0.6 (2015];11\(52\):3091-3097. )54.6 (A)55.3 (vailable)-10.4 ( )]TJ
1.89 Tw T*
[(from: http://www)105.9 (.sciencedirect.com/science/article/pii/)]TJ
0.01 Tw T*
(S0304541214707450)Tj
-0.057 Tw -1.772 -1.25 Td
(2.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Ministerio de Salud. Estrategia Sanitaria Nacional de P)47.3 (revencion)-10.4 ( )]TJ
0.087 Tw T*
[(y Control de la )18.2 (T)129.8 (uberculosis. Lima: Ministerio de Salud; 2010.)-10.2 ( )]TJ
0.01 Tw T*
(1-2.)Tj
0.386 Tw 30.118 75.192 Td
(3.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(T)129.8 (uli S. General P)47.2 (rinciples of Osteoarticular )18.1 (T)129.8 (uberculosis.)-10.2 ( )]TJ
0.249 Tw T*
[(Clinical )-0.6 (Orthopaedics )-0.7 (& )-0.7 (R)40.5 (elated )-0.7 (R)40.5 (esearch )-0.7 ([Internet]. )-0.7 (2002)-10.5 ( )]TJ
0.166 Tw T*
[([cited 12 October 2015]; 398:11-19. )54.9 (A)55.3 (vailable from:http://)]TJ
0.043 Tc -0.043 Tw T*
[(j)0.6 (o)0.6 (ur)0.6 (nals.lww)106 (.co)0.6 (m/co)0.6 (r)0.6 (r)0.6 (/Abs)0.5 (tr)0.6 (act/2002/05000/Gener)0.5 (al_)]TJ
-0.01 Tc 0.01 Tw T*
[(P)47.3 (rinciples_of_Osteoarticular_T)129.8 (uberculosis.3.aspx)]TJ
0.09 Tw -1.772 -1.25 Td
(4.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Ministerio de Salud. Situaci\363n de la )17.8 (T)129.8 (uberculosis en el P)47.3 (er\372.)-10.2 ( )]TJ
-0.027 Tw T*
[(Lima: Direccion General de Salud de las P)47.2 (ersonas; 2008. 2-78.)]TJ
0.103 Tw -1.772 -1.25 Td
(5.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Alarc\363n )54.6 (A. Situaci\363n de )-0.6 (la )17.6 (T)129.8 (uberculosis en )-0.6 (el P)47.3 (er\372 y P)47.3 (ol\355tica)-10.4 ( )]TJ
-0.045 Tw T*
[(Nacional para su Control. )55 (Arequipa: Ministerio de Salud; 2014.)-10.2 ( )]TJ
0.01 Tw T*
(1-68.)Tj
-0.008 Tw -1.772 -1.25 Td
(6.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Chen S, Zhao L, Dong W)92.3 (, Gu )18 (Y)160.8 (, Li )18.1 (Y)160.8 (, Dong L, et al. )18 (T)0.5 (he Clinical)-9.9 ( )]TJ
0.153 Tw T*
[(Features and Bacteriological Characterizations of Bone and)-10.1 ( )]TJ
0.122 Tw T*
[(J)0.5 (oint )17.6 (T)129.9 (uberculosis in China. Sci R)40.5 (ep. [Internet]. 2015 [cited)-10.1 ( )]TJ
0.018 Tw T*
[(10 October 2015];5:11084. )54.7 (A)55.3 (vailable from: http://www)105.8 (.ncbi.)]TJ
0.01 Tw T*
(nlm.nih.gov/pubmed/26053666)Tj
0.097 Tw -1.772 -1.25 Td
(7.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Iseman MD. )54.9 (A)55.3 ( clinician\222)68.7 (s guide to tuberculosis. P)47.3 (hiladelphia:)-10.2 ( )]TJ
0 Tw T*
[(Lippincott, W)13.6 (illiams & W)13.6 (ilkins; 2000.162)]TJ
0.27 Tw -1.772 -1.25 Td
(8.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Kramer N, R)40.5 (osenstein E. Rheumatologic manifestations of)-9.6 ( )]TJ
0 Tw T*
[(tuberculosis. Bull Rheum Dis. 1997; 46\(3\):5-8.)-10.2 ( )]TJ
0.474 Tw -1.772 -1.25 Td
(9.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Lidder S, Lang K, Haroon M, Shahidi M, El-Guindi M.)-10.2 ( )]TJ
-0.06 Tw T*
[(T)129.8 (uberculosis of the knee .Orthopedic R)40.5 (eviews. 2009; 1\(2\):e24.)-10.2 ( )]TJ
0.529 Tw -1.772 -1.25 Td
(10.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(P)47.3 (asion E, Leung J. )17.7 (T)0.5 (B arthritis. Current Orthopaedics)-9.8 ( )]TJ
0.445 Tw T*
[([Internet]. 2000 [cited 5 October 2015]; 14\(3\):197-204.)-10.2 ( )]TJ
0.958 Tw T*
[(A)55.3 (vailable from: http://www)105.9 (.sciencedirect.com/science/)]TJ
0.01 Tw T*
(article/pii/S0268089000901063)Tj
-0.015 Tw -1.772 -1.25 Td
(11.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(W)55.6 (atts )-0.7 (HG, )-0.7 (Lifeso )-0.7 (RM. )17.4 (T)129.8 (uberculosis )-0.7 (of )-0.7 (bones )-0.7 (and )-0.8 (joints. )-0.7 (J )-0.7 (Bone)-10.4 ( )]TJ
0 Tw T*
[(J)0.5 (oint Surg )54.9 (Am. 1996; 78:288\22698.)-10.2 ( )]TJ
-0.004 Tw -1.772 -1.25 Td
(12.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Ministerio de Salud. Norma )17.7 (T\351cnica de Salud para la )54.8 (Atenci\363n)-10.4 ( )]TJ
0.224 Tw T*
[(Integral de las P)47.3 (ersonas )55.2 (Afectadas por )18.1 (T)129.8 (uberculosis. Lima:)-10.2 ( )]TJ
0 Tw T*
[(Ministerio de Salud; 2013. 21-30.)-10.2 ( )]TJ
0.018 Tw -1.772 -1.25 Td
(13.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(Y)92.5 (ao )-0.6 (DC, Sartoris DJ. Musculoskeletal )-0.6 (tuberculosis. Radiol )-0.6 (Clin)-10.3 ( )]TJ
0 Tw T*
[(North )54.9 (Am. 1995; 33\(4\):679-89.)-10.2 ( )]TJ
-0.087 Tw -1.772 -1.25 Td
(14.)Tj
/Span<>> BDC
( )Tj
EMC
1.772 0 Td
[(T)125 (ang X, Zhu J)0.5 (, Li Q, Chen G, Fu W)92.2 (, Li J. K)31.5 (nee arthrodesis using a)-10.4 ( )]TJ
-0.003 Tw T*
[(unilateral external fixator combined with crossed cannulated)-10.1 ( )]TJ
0.206 Tw T*
[(screws for the treatment of end-stage tuberculosis of the)-10.4 ( )]TJ
0.23 Tw T*
[(knee. BMC Musculoskelet Disord. [Internet]. 2015 [cited 7)-10.5 ( )]TJ
-0.018 Tw T*
[(October 2015];16:197. )55.2 (A)55.3 (vailable from: http://www)105.9 (.ncbi.nlm.)]TJ
0.01 Tw T*
(nih.gov/pubmed/26286256)Tj
/CS0 cs 1 scn
/GS1 gs
/TT2 1 Tf
0 Tc 0 Tw -1.772 -2.5 Td
(Fuentes de financiamiento:)Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0 -1.2 TD
(Este art\355culo ha sido financiado por los autores.)Tj
/CS0 cs 1 scn
/GS1 gs
/TT2 1 Tf
0 -2.45 TD
(Conflictos de inter\351s:)Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
0 -1.2 TD
(Los autores declaran no tener ning\372n conflicto de inter\351s.)Tj
/CS0 cs 1 scn
/GS1 gs
/TT2 1 Tf
0 -2.45 TD
(Correspondencia:)Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.01 Tc 0 -1.25 TD
[(Erika Luc\355a P)47.2 (ilco Guerra)-10.4 ( )]TJ
T*
[(Direcci\363n: )55 (A)55.3 (v)134.5 (. )54.9 (A)55.3 (viaci\363n 2382, Dpto. 501, San Borja.)]TJ
T*
[(T)124.9 (el\351fono: 942958972)]TJ
T*
[(Correo electr\363nico: erika.pilco2@)0.5 (gmail.com)]TJ
ET
/CS0 cs 1 scn
/GS1 gs
333.071 127.906 170.079 36.851 re
f
BT
0 0 0 0 k
0 Tc 9 0 0 9 345.5433 148.5834 Tm
[(R)40.5 (ecibido: 16 de junio de 2016)]TJ
0 -1.222 TD
(Aprobado: 08 de julio de 2016)Tj
0 0 0 1 k
/GS0 gs
-0.117 Tw -18.677 65.55 Td
[(R)40.5 (eporte )-1.4 (de )-1.2 (caso )-0.6 (de )-1.2 (tuberculosis )-1.5 (osteoarticular: )-2 (dificultad )]TJ
0 Tw 3.262 -1.556 Td
(diagn\363stica y probable infecci\363n primaria)Tj
-14.789 -75.626 Td
(Horiz Med 2017; 17\(1\): 76-80)Tj
ET
endstream
endobj
16 0 obj
<>
endobj
17 0 obj
<>
endobj
31 0 obj
<>
endobj
36 0 obj
<>
endobj
37 0 obj
<>stream
H\݊0s^m
ۂvlCdJ6ѓ$eu\7A{ 5,oSNY|۾*!e'+H>hqC3\q`
_e &H(>RGHlU5M4G|-fkv7T&Q9(z:(qsRQfsLE&2\8'בKO=Vx˼16ڽ.G,L1Z|j3Y